This website isn’t supported by Internet Explorer. We recommend that you use a different browser (e.g. Edge, Chrome, Firefox, Safari, or similar) for the best experience of our content.
24.07.2025 | Curtir Curtir

1.

Singh S, Allen AM, Wang Z, et al. Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies. Clin Gastroenterol Hepatol. 2015;13(4):643-54;

2.

Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Oiver Diseases. Hepatol Baltim Md. 2018;67(1):328-57;

3.

Bansal SK, Bansal MB. Pathogenesis of MASLD and MASH - role of insulin resistance and lipotoxicity. Aliment Pharmacol Ther. 2024;59 Suppl 1:S10-S22;

4.

Rinella E, Neuschwander-Tetri BA, Siddiqui MS, et al. AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease. Hepatol Baltim Md. 2023;77(5):1797-1835;

5.

Muthiah D, Cheng Han N, Sanyal AJ. A clinical overview of non-alcoholic fatty liver disease: A guide to diagnosis, the clinical features, and complications - What the non-specialist needs to know. Diabetes Obes Metab. 2022;24 Suppl 2:3-14;

6.

Ratziu V et al. J Hepatol. 2015;62:S65–S75; Rinella ME et al. Terap Adv Gastroenterol. 2016;9:4-12;

7.

Polanco-Briceno S et al. Observações sobre o BMC Res. 2016;9:157;

8.

Zelber-Sagi S et al. Terap Adv Gastroenterol. 2016;9:392-407;

9.

Ofosu A et al. Ann Gastroenterol 2018;31:288–95.